8VC — 2022 Investments

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Executive Officer, Director)

BoardIvan Trifunovich(Director)John Wesley(Director)

Board seatAlex Kolicich· per SEC Form D

Co-investorsAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital ManagementTaiho Ventures, LLC+1 more

Hawthorne, US

Board seatAlex Moore· per SEC Form D

Co-investorsBedrock Capital

Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.

BiotechDeep TechHealthtechMenlo Park, US

Colin James Bell Harvey(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)Maureen Hillenmeyer(CEO & Co-Founder)in

BoardAlex Kolich(Director)

Board seatAlex Kolicich· per SEC Form D

Co-investorsB3 HoldingNextech InvestSoftBank Vision FundThe Column GroupCasdin CapitalTwo Sigma Ventures

AI diagnostics company whose FDA-cleared autonomous system detects diabetic retinopathy from retinal images in primary care.

HealthtechCoralville, US

James Folk(Manager, Vice President & Secretary)Michael D Abramoff(Manager & President)Gary Seamans(Executive Officer, Director)Benjamin Clark(Chief Operating Officer & Vice President)

BoardWilliam Frist(Manager)Howard H Leach(Manager)

Board seatDrew Oetting· per SEC Form D · $76.4M raise · filed Aug 2022

Co-investorsFrist Cressey Ventures

An online marketplace offering a wide range of products including packaging materials, industrial safety equipment, home and kitchen supplies, tools, electrical systems, hardware, paint, automotive parts, and other industrial and consumer goods.

B2B MarketplacesE-commerceBogota D.C., CO

Board seatJake Medwell· per SEC Form D

Co-investorsAvenir Growth CapitalCapria VenturesMONASHEESHTwentySoftBank GroupTiger Global Management

CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies.

BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US

Daniel Getts(Founder and CEO)inBrett Kaplan(Chief Financial and Business Officer)inMarcus Lowe(Executive Officer, Director)Dhruv Amin(Executive Officer, Director)

Co-investorsRaptor GroupNewpath Partners